Skip to main content
OpenTrials
Completed

NCT Number: NCT02663609

Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome

Chart review study to collect patient data from medical charts of patients who have been treated with Korlym® for the treatment of ACTH independent adrenal Cushing's Syndrome.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cushing's Syndrome Adrenal Gland Diseases Adrenocortical Hyperfunction Cushing Syndrome Endocrine System Diseases

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Observational

About this study

A retrospective, multi-center, chart review study to collect patient data from medical charts of patients who have been treated with Korlym® for the treatment of ACTH independent adrenal Cushing's Syndrome. Treatment with Korlym® will be a minimum 3 months in duration with follow-up of a minimum 3 months. Only sites that have been identified to have patients appropriate for this protocol will be invited to participate.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosed with ACTH independent endogenous Cushing's Syndrome
  • Available adrenal imaging prior to being treated with Korlym®
  • Treated with Korlym® and followed for at least 3 months (follow-up data should be available)

Exclusion criteria

  • Diagnosed with adrenocortical carcinoma
  • Participant in any clinical trial(s) during the observational period

Treatment and study plan

No intervention

Other

No treatment (intervention) was administered.

Primary outcomes

  1. Drug Utilization Patterns as assessed by chart review

    Time frame: up to 4 years

    The retrospective review would analyze the drug utilization patterns of patients treated with Korlym

Secondary outcomes

  1. Clinical Outcomes as assessed by chart review

    Time frame: up to 4 years

    The retrospective review would analyze outcomes measures (vitals, clinical assessments, etc) in patients treated with Korlym

Sponsors and collaborators

Lead sponsor

Corcept Therapeutics

Industry

Registry information

Acronym: RE-KLAIM

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Jan 26, 2016
Registry last updated
Jun 1, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.